Business Description
Sigyn Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US82674U2050
Share Class Description:
SIGY: Ordinary SharesTotal Employee Number:
4Description
Sigyn Therapeutics Inc is a development-stage Company advancing CardioDialysisTM, a next generation blood purification technology that enables continuous broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream. The company has also designed a pipeline of cancer therapies, including ImmunePrepTM to optimize the delivery of immunotherapeutic antibodies; ChemoPrepTM to enhance the targeted delivery of chemotherapy; and ChemoPureTM to reduce the toxicity of chemotherapy. The company currently operates in one business segment.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.03 | |||||
Equity-to-Asset | -43.51 | |||||
Debt-to-Equity | -0.48 | |||||
Debt-to-EBITDA | -1.05 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 12.5 | |||||
3-Year EPS without NRI Growth Rate | 0.9 | |||||
3-Year FCF Growth Rate | 30.9 | |||||
3-Year Book Growth Rate | -113.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 49.73 | |||||
9-Day RSI | 48.72 | |||||
14-Day RSI | 47.69 | |||||
3-1 Month Momentum % | -27.84 | |||||
6-1 Month Momentum % | -93 | |||||
12-1 Month Momentum % | -98.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.02 | |||||
Quick Ratio | 0.02 | |||||
Cash Ratio | 0.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19.9 | |||||
Shareholder Yield % | -235.73 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -1501.4 | |||||
ROIC % | -88.3 | |||||
3-Year ROIIC % | -38.68 | |||||
ROC (Joel Greenblatt) % | -2060.89 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -1.08 | |||||
EV-to-EBITDA | -1.08 | |||||
EV-to-FCF | -3.09 | |||||
Earnings Yield (Greenblatt) % | -92.59 | |||||
FCF Yield % | -580.75 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:SIGY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sigyn Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.93 | ||
| Beta | 1.0709 | ||
| 3-Year Sharpe Ratio | -0.31 | ||
| 3-Year Sortino Ratio | -0.47 | ||
| Volatility % | 150.89 | ||
| 14-Day RSI | 47.69 | ||
| 14-Day ATR ($) | 0.007118 | ||
| 20-Day SMA ($) | 0.03192 | ||
| 12-1 Month Momentum % | -98.75 | ||
| 52-Week Range ($) | 0.0103 - 5 | ||
| Shares Outstanding (Mil) | 5.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sigyn Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sigyn Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 111 days | ||
| Second quarter earnings results for 2026 | 2026-09-04 | In 41 days | ||
| General meeting for 2025 | 2026-07-28 | In 3 days | ||
| Annual report for 2025 | 2026-07-15 | 0.03 (-35.90%) | ||
| Guidance call for 2026 | 2026-06-24 15:00 | 0.04 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 2.00 (+0.00%) | ||
| LD Micro Main Event XIX | 2025-10-21 16:00 | 2.00 (+0.00%) | ||
| Sigyn Therapeutics, Inc. Life Sciences Virtual Investor Forum | 2025-09-18 15:00 | 3.50 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-09-05 | 4.60 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-20 | 3.53 (+0.00%) |
Show
Entries
Sigyn Therapeutics Inc Frequently Asked Questions
What is Sigyn Therapeutics Inc(SIGY)'s stock price today?
The current price of SIGY is $0.03. The 52 week high of SIGY is $5.00 and 52 week low is $0.01.
When is next earnings date of Sigyn Therapeutics Inc(SIGY)?
The next earnings date of Sigyn Therapeutics Inc(SIGY) is 2026-09-04 Est..
Does Sigyn Therapeutics Inc(SIGY) pay dividends? If so, how much?
Sigyn Therapeutics Inc(SIGY) does not pay dividend.
Guru Commentaries on OTCPK:SIGY
No articles.
Press Release
Articles on Sigyn Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers